Venom Week V, International Scientific Symposium, East Carolina University, Greenville, NC, USA, Abstracts, Part I. March 9 - 12, 2016 Sean P. Bush, MD, FACEP, Symposium Coordinator and Chair Mildred Carraway, RN, BSN, Meeting Organizer Steven A. Seifert MD, FAACT, FACMT, Abstracts Editor Published in: Toxicon 117 (2016) 102-111. 1. Antivenom-Antidotes The Efficacy of Early Fab Antivenom versus Placebo Plus Optional Rescue Therapy on Recovery from Copperhead Snake Envenomation Charles J. Gerardo and Eric J. Lavonas on behalf of the Copperhead Snakebite Recovery Outcome Group*
[email protected] Background: Copperhead envenomation accounts for >40% of the approximately 9000 snake envenomation patients treated annually in the United States. Although copperhead envenomation rarely produces shock, medically significant bleeding or death, local tissue injury can be significant. Previous studies have shown limb dysfunction lasting several weeks in most of patients, and at least a year in some copperhead victims. Whether early antivenom administration improves the severity or duration of this limb dysfunction is not known. Objective: To compare the recovery of copperhead envenomated patients treated with antivenom to those receiving placebo, with rescue therapy available for patients who develop severe envenomation. Methods: We conducted a multi-center, double-blind, placebo controlled study of treatment with Fab antivenom (Crotalidae Polyvalent Immune Fab® (ovine origin), BTG, West Conshohocken, PA) (FabAV) versus placebo for mild and moderate copperhead envenomated patients. Patients ≥12 years old and presenting within 24 hours were randomized 2:1 to receive 6 vials of FabAV or placebo, repeated once if necessary to achieve initial control. Standard maintenance dosing (2 vials of FabAV or placebo every 6 hours for 3 doses) was then administered.